Ono Pharmaceutical Company Description
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide.
It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia.
The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.
In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis.
The company has collaborations with Adimab LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and Sibylla Biotech for central nervous system disorders.
Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
| Country | Japan |
| Founded | 1717 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 4,287 |
| CEO | Gyo Sagara |
Contact Details
Address: 8-2, Kyutaromachi 1-chome Osaka, 541-8564 Japan | |
| Phone | 81 6 6263 5670 |
| Website | ono-pharma.com |
Stock Details
| Ticker Symbol | OPHLF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3197600004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gyo Sagara | Chief Executive Officer and Chairman of the Board |
| Toichi Takino Ph.D. | President, Chief Operating Officer and Representative Director |
| Toshihiro Tsujinaka | EVice President, Executive Director of Corporate Strategy and Planning, Human Resources Division and Representative Director |
| Masaki Ito | Corporate Executive Officer and Div. Director of Corporate Strategy, Planning and Business Management Div. |
| Takehiro Yamada | Corporate Officer and Head of Risk and Compliance Management Department |
| Masayuki Tanigawa | Corporate Officer and Head of Business Strategy, License |
| Hiromu Habashita Ph.D. | Corporate Officer and Deputy Executive Director, Discovery & Research |
| Shinji Takai M.D., Ph.D. | Corporate Officer and Head of Medical Affairs |
| Satoshi Takahagi | Senior Director of EHS Promotion and Corporate Officer |
| Akira Takada | Corporate Executive Officer and Executive Director of CMC & Production |